|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US7090843B1
(en)
†
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
CA2467242A1
(en)
*
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
CA2471645A1
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
|
IL162835A0
(en)
*
|
2002-01-09 |
2005-11-20 |
Medarex Inc |
Human monoclonal antibodies against cd30
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
DK1545613T3
(da)
*
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
WO2006039644A2
(en)
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating cd30 positive lymphomas
|
|
ES2498794T3
(es)
|
2005-02-18 |
2014-09-25 |
Medarex, L.L.C. |
Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
US8257706B2
(en)
*
|
2006-08-25 |
2012-09-04 |
Seattle Genetics, Inc. |
CD30 binding agents and uses thereof
|
|
EP2176295B1
(en)
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
PE20090943A1
(es)
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
EA020696B1
(ru)
*
|
2007-10-12 |
2015-01-30 |
Сиэтл Дженетикс, Инк. |
Способ лечения лимфомы ходжкина с использованием комбинации гемцитабина и конъюгата антитела против cd30 с ауристатином
|
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
EP3581206B8
(en)
|
2010-10-22 |
2025-02-19 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
EP2793947B1
(en)
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
US9926373B2
(en)
*
|
2012-04-27 |
2018-03-27 |
Novo Nordisk A/S |
Human CD30 ligand antigen binding proteins
|
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
US9089614B2
(en)
|
2012-12-21 |
2015-07-28 |
Bioalliance C.V. |
Hydrophilic self-immolative linkers and conjugates thereof
|
|
MX2015012549A
(es)
|
2013-03-15 |
2016-06-21 |
Abbvie Deutschland |
Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
|
|
EP2968589A1
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Antibody drug conjugate (adc) purification
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
CA2908380A1
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
|
NZ758049A
(en)
|
2013-10-15 |
2024-03-22 |
Seagen Inc |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
|
US10562977B2
(en)
|
2014-01-29 |
2020-02-18 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
US9950077B2
(en)
|
2014-06-20 |
2018-04-24 |
Bioalliance C.V. |
Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
CA2989269C
(en)
|
2015-06-15 |
2020-09-22 |
Robert Yongxin Zhao |
Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
FI3380620T3
(fi)
|
2015-11-23 |
2024-08-01 |
Novartis Ag |
Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
|
|
RU2018127657A
(ru)
|
2015-12-30 |
2020-01-31 |
Новартис Аг |
Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
|
|
IL260289B
(en)
|
2016-01-08 |
2022-08-01 |
Bioalliance Cv |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
CN110022938A
(zh)
|
2016-11-14 |
2019-07-16 |
千禧制药公司 |
抗cd30抗体药物缀合物的非成年人给药
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018158716A1
(en)
|
2017-03-02 |
2018-09-07 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11795229B2
(en)
|
2017-10-11 |
2023-10-24 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
RU2020116579A
(ru)
|
2017-10-25 |
2021-11-25 |
Новартис Аг |
Способы получения клеток, экспрессирующих химерный антигенный рецептор
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US20220226439A1
(en)
|
2017-11-01 |
2022-07-21 |
Seagen Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
CN117126279A
(zh)
|
2018-03-20 |
2023-11-28 |
鸿运华宁（杭州）生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
|
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3856777A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
US20200102399A1
(en)
|
2018-10-01 |
2020-04-02 |
Seattle Genetics, Inc. |
Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
|
|
JP7699542B2
(ja)
|
2018-11-20 |
2025-06-27 |
コーネル ユニバーシティー |
放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
WO2020210719A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Management, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
CN112125915A
(zh)
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
AU2020351751A1
(en)
|
2019-09-25 |
2022-04-21 |
Seagen Inc. |
Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
CN114929284A
(zh)
|
2019-10-04 |
2022-08-19 |
西根公司 |
喜树碱肽缀合物
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
WO2021091815A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
JP7821733B2
(ja)
|
2020-01-22 |
2026-02-27 |
上海森輝医薬有限公司 |
エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
|
|
EP4096713A1
(en)
|
2020-01-31 |
2022-12-07 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
|
CN115103858B
(zh)
|
2020-03-25 |
2025-07-15 |
江苏恒瑞医药股份有限公司 |
一种抗体药物偶联物的制备方法
|
|
BR112022019073A2
(pt)
|
2020-03-25 |
2022-11-08 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
|
|
AU2021251875A1
(en)
|
2020-04-10 |
2022-11-03 |
Seagen Inc. |
Charge variant linkers
|
|
CA3183602A1
(en)
|
2020-05-13 |
2021-11-18 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
|
|
JP2023529211A
(ja)
|
2020-06-11 |
2023-07-07 |
ノバルティス アーゲー |
Ｚｂｔｂ３２阻害剤及びその使用
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
JP2024503508A
(ja)
|
2021-01-15 |
2024-01-25 |
シージェン インコーポレイテッド |
免疫調節性抗体－薬物コンジュゲート
|
|
BR112023018676A2
(pt)
|
2021-03-18 |
2023-10-10 |
Seagen Inc |
Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117597150A
(zh)
|
2021-04-20 |
2024-02-23 |
思进公司 |
抗体依赖性细胞毒性的调节
|
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
|
AU2022283467A1
(en)
|
2021-05-28 |
2023-12-07 |
Seagen Inc. |
Anthracycline antibody conjugates
|
|
MX2024005080A
(es)
|
2021-10-29 |
2024-05-13 |
Seagen Inc |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
CN114891101B
(zh)
*
|
2021-12-02 |
2023-06-16 |
吉林省农业科学院 |
一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
|
|
WO2023178289A2
(en)
|
2022-03-17 |
2023-09-21 |
Seagen Inc. |
Camptothecin conjugates
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
EP4518905A1
(en)
|
2022-05-06 |
2025-03-12 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
CN120076829A
(zh)
|
2022-10-18 |
2025-05-30 |
明治制果药业株式会社 |
T细胞肿瘤的治疗剂
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
CN121311250A
(zh)
|
2023-03-22 |
2026-01-09 |
信立泰生物医药公司 |
抗5t4抗原结合结构域、抗体-药物缀合物及其使用方法
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
AR134171A1
(es)
|
2023-10-24 |
2025-12-10 |
Seagen Inc |
Compuestos quimioterapéuticos y métodos de uso
|
|
WO2025096626A1
(en)
|
2023-10-31 |
2025-05-08 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025169056A1
(en)
|
2024-02-06 |
2025-08-14 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
CN119331093B
(zh)
*
|
2024-11-04 |
2025-07-11 |
武汉伊莱瑞特生物科技股份有限公司 |
一种抗CD30的兔源Fab抗体及其制备方法和应用
|